Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials.
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
revised:
11
06
2024
received:
11
06
2024
accepted:
14
06
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
1
8
2024
Statut:
aheadofprint
Résumé
We explored the relationship between achievement of clinical disease control and improvements in and normative values for patient-reported outcomes (PROs), including quality of life (QoL) measures, in patients with psoriatic arthritis (PsA). This was a post hoc analysis of 104-week data from the SELECT-PsA 1 and 2 trials in adults with PsA and inadequate response to one or more conventional synthetic (SELECT-PsA 1) or biologic (SELECT-PsA 2) disease-modifying antirheumatic drug. Patients were initially randomized to upadacitinib 15 mg once daily (QD) to placebo switched to upadacitinib 15 mg QD at week 24 or to adalimumab 40 mg every other week (SELECT-PsA 1 only), and data were pooled across treatments and analyzed. We evaluated several clinical disease control measures (minimal disease activity [MDA]; very low disease activity [VLDA]; and low disease activity [LDA] and/or remission by Disease Activity in Psoriatic Arthritis [DAPSA], Psoriatic Arthritis Disease Activity Score [PASDAS], and Routine Assessment of Patient Index Data 3 [RAPID3]) and examined their associations with improvements and normative values for various PROs. A total of 1,069 and 317 patients were analyzed for SELECT-PsA 1 and 2, respectively. In both studies, responders (patients who achieved MDA or VLDA, and DAPSA, PASDAS, and RAPID3 LDA or remission) at week 104 achieved more marked changes from baseline, and more responders achieved normative values in PROs compared with nonresponders (most nominal P < 0.0001). Furthermore, numerically larger proportions of responders achieved minimal clinically important differences across PROs compared with nonresponders in both studies. In addition, patients who achieved MDA or VLDA were more likely to achieve DAPSA, PASDAS, and RAPID3 LDA or remission (all nominal P < 0.0001) for upadacitinib 15 mg QD and when treatment arms were pooled. Patients with PsA who achieve clinical disease control are more likely to achieve improvements and normative values in PROs and QoL measures, which reinforces disease control as a treatment target.
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024 AbbVie and The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Coates LC, Soriano ER, Corp N, et al; GRAPPA Treatment Recommendations domain subcomittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18(8):465–479.
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79(6):700–712.
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69(1):48–53.
Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43(2):371–375.
Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69(8):1441–1447.
Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72(6):986–991.
Coates LC, Tillett W, Shaddick G, et al. Value of the routine assessment of Patient Index Data 3 in patients with psoriatic arthritis: results from a tight‐control clinical trial and an observational cohort. Arthritis Care Res (Hoboken) 2018;70(8):1198–1205.
Leung YY, Tillett W, deWit M, et al. Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA‐OMERACT working group. J Rheumatol 2023;50(suppl 2):53–57.
Aouad K, Moysidou G, Rakotozafiarison A, et al. Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients. Semin Arthritis Rheum 2021;51(4):888–894.
Wervers K, Luime JJ, Tchetverikov I, et al. Influence of disease manifestations on health‐related quality of life in early psoriatic arthritis. J Rheumatol 2018;45(11):1526–1531.
Salaffi F, Carotti M, Gasparini S, et al. The health‐related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.
Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT‐494). BMC Rheumatol 2018;2:23.
McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 2021;384(13):1227–1239.
Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT‐PsA 2. Ann Rheum Dis 2021;80(3):312–320.
McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non‐biological therapy: 56‐week data from the phase 3 SELECT‐PsA 1 study. RMD Open 2021;7(3):e001838.
Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56‐week data from the randomized controlled Phase 3 SELECT‐PsA 2 study. Rheumatol Ther 2021;8(2):903–919.
Mease P, Setty A, Papp K, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3‐year results from the open‐label extension of the randomised controlled phase 3 SELECT‐PsA 2 study. Clin Exp Rheumatol 2023;41(11):2286–2297.
McInnes IB, Kato K, Magrey M, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2‐year results from the phase 3 SELECT‐PsA 1 study. Rheumatol Ther 2023;10(1):275–292.
Strand V, Mease PJ, Soriano ER, et al. Improvement in patient‐reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT‐PsA 1. Rheumatol Ther 2021;8(4):1789–1808.
Strand V, Van den Bosch F, Ranza R, et al. Patient‐reported outcomes in psoriatic arthritis patients with an inadequate response to biologic disease‐modifying antirheumatic drugs: SELECT‐PsA 2. Rheumatol Ther 2021;8(4):1827–1844.
Tillett W, Costa L, Jadon D, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria–a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012;39(1):154–156.
Orbai AM, Ogdie A. Patient‐reported outcomes in psoriatic arthritis. Rheum Dis Clin North Am 2016;42(2):265–283.
Ward L, Oliffe M, Kane B, et al. Correlation of patient‐reported routine assessment of patient index data with clinical measures of disease activity in psoriatic arthritis. Int J Rheum Dis 2022;25(5):584–591.
Cook CE. Clinimetrics corner: the minimal clinically important change score (MCID): a necessary pretense. J Man Manip Ther 2008;16(4):E82–E83.
Strand V, Boers M, Idzerda L, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38(8):1720–1727.
O'Connor PJ. Normative data: their definition, interpretation, and importance for primary care physicians. Fam Med 1990;22(4):307–311.
Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient‐rated importance and satisfaction. J Rheumatol 2011;38(11):2461–2465.
Krishnan E, Sokka T, Häkkinen A, et al. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50(3):953–960.
Hinz A, Kohlmann T, Stöbel‐Richter Y, et al. The quality of life questionnaire EQ‐5D‐5L: psychometric properties and normative values for the general German population. Qual Life Res 2014;23(2):443–447.
Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
Anderson JK, Zimmerman L, Caplan L, et al. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28‐Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score‐II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index‐5 (RADAI‐5), Chronic Arthritis Systemic Index (CASI), Patient‐Based Disease Activity Score With ESR (PDAS1) and Patient‐Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI‐RA). Arthritis Care Res (Hoboken) 2011;63(suppl 11):S14–S36.
Tillett W, Lin CY, Zbrozek A, et al. A threshold of meaning for work disability improvement in psoriatic arthritis measured by the Work Productivity and Activity Impairment questionnaire. Rheumatol Ther 2019;6(3):379–391.
Kavanaugh A, Mease PJ, Douglas K, et al. AB0547 Association between achievement of low disease activity or remission with improvement in quality of life in upadacitinib‐treated patients in the phase 3 SELECT‐PsA 1 and 2 studies. Ann Rheum Dis 2021;80(suppl 1):1306–1307.
Coates LC, Orbai AM, Morita A, et al. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health‐related quality of life and productivity. BMC Rheumatol 2018;2:24.
Coates LC, Nash P, Kvien TK, et al. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2‐year results from the FUTURE 2 study. Semin Arthritis Rheum 2020;50(4):709–718.
Coates LC, Bushmakin AG, FitzGerald O, et al. Relationships between psoriatic arthritis composite measures of disease activity with patient‐reported outcomes in phase 3 studies of tofacitinib. Arthritis Res Ther 2021;23(1):94.
Mlcoch T, Tuzil J, Sedova L, et al. Mapping quality of Life (EQ‐5D) from DAPSA, clinical DAPSA and HAQ in psoriatic arthritis. Patient 2018;11(3):329–340.
Gorlier C, Orbai AM, Puyraimond‐Zemmour D, et al. Comparing patient‐perceived and physician‐perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Ann Rheum Dis 2019;78(2):201–208.
Sousa M, Lubrano E, Smolen JS, et al. Patient‐defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries. Joint Bone Spine 2023;90(3):105511.
Smolen JS, Lubrano E, Kishimoto M, et al. POS1025 Comparison of composite indices for disease activity in patients with psoriatic arthritis treated with upadacitinib: a post‐hoc analysis from SELECT‐PsA 1. Ann Rheum Dis 2022;81(suppl 1):824.
Coates LC, Strand V, Wilson H, et al. Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open 2019;5(2):e001002.